Virtual Library

Start Your Search

D. Rassam



Author of

  • +

    P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P2.01-079 - A Phase I Study Comparing PF-06439535 (A Potential Biosimilar) with Bevacizumab (ID 698)

      09:30 - 17:00  |  Author(s): D. Rassam

      • Abstract
      • Slides

      Background:
      PF-06439535, a potential biosimilar to bevacizumab, is a humanized monoclonal IgG1 antibody that targets the vascular endothelial growth factor. This study (B7391001) compared the pharmacokinetics (PK) of PF-06439535 to bevacizumab sourced from the US (bevacizumab-US) and EU (bevacizumab–EU), and the PK of bevacizumab-EU to bevacizumab–US in healthy male volunteers.

      Methods:
      In this double-blind study, 102 healthy males, aged 21-55 years, were randomized 1:1:1 to receive a single 5 mg/kg intravenous dose of PF-06439535, bevacizumab-US, or bevacizumab-EU. One subject discontinued before dosing. Assessments for PK were conducted for 71 days, with extended safety and immunogenicity assessments up to 100 days postdose. PK similarity was achieved if 90% confidence intervals (CIs) for the test-to-reference ratios of the maximum concentration (C~max~), the area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC~T~), and AUC from time 0 extrapolated to infinity (AUC~0-∞~) were within 80.00%–125.00%.

      Results:
      Ninety-seven subjects were eligible and included in the PK analysis. The demographics of the PK eligible subjects were comparable among the 3 treatment groups. The 3 study drugs exhibited similar PK parameters (Table 1). For the comparisons of PF-06439535 to bevacizumab-EU or bevacizumab-US, and of bevacizumab-EU to bevacizumab-US, the 90% CIs for the ratios of C~max~, AUC~T~, and AUC~0-∞~ were all within 80.00%–125.00% (Table 2). Treatment-related adverse events were reported in 15.2%, 25.7%, and 18.2% of subjects in the PF-06439535, bevacizumab-EU, and bevacizumab-US treatment arms, respectively. Table 1: Mean (±SD) PK Parameter Estimates

      Parameters (units) PF-06439535 Bevacizumab-EU Bevacizumab-US
      N 32 33 32
      C~max~ (µg/mL) 142.9 ± 20.3 137.0 ± 20.5 130.0 ± 18.2
      AUC~T~ (µg•hr/mL)[a] 40840 ± 6411 41010 ± 6711 38920 ± 4566
      AUC~0-∞~ (µg•hr/mL) 43080 ± 7103 43830 ± 8326 41450 ± 5350
      [a]AUC~T~ was ≥80% of the corresponding AUC~0-∞~ in all 97 PK eligible subjects. Table 2: Comparisons of Pharmacokinetic Exposure Parameters between Test and Reference Products
      Comparison (Test to Reference) Parameters, units Test[a] Reference[a] Test/Reference Ratio (%) 90% CI for Ratio
      PF-06439535 to bevacizumab-EU C~max~, µg/mL 141.5 135.5 104.42 98.36–110.84
      AUC~T~, µg•hr/mL 40330 40490 99.62 93.69–105.93
      AUC~0-∞~, µg•hr/mL 42490 43100 98.58 92.16–105.44
      PF-06439535 to bevacizumab-US C~max~, µg/mL 141.5 128.9 109.79 103.38–116.60
      AUC~T~, µg•hr/mL 40330 38660 104.32 98.06–110.97
      AUC~0-∞~, µg•hr/mL 42490 41120 103.33 96.55–110.58
      Bevacizumab-EU to bevacizumab-US C~max~, µg/mL 135.5 128.9 105.15 99.05–111.62
      AUC~T~, µg•hr/mL 40490 38660 104.71 98.48–111.34
      AUC~0-∞~, µg•hr/mL 43100 41120 104.82 98.00–112.12
      [a]Adjusted geometric means

      Conclusion:
      This study demonstrates PK similarity of PF-06439535 to both bevacizumab-US and bevacizumab-EU, and of bevacizumab-EU to bevacizumab-US. The safety profile was similar in the 3 treatment groups with no significant safety findings reported.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.